Avid Bioservices

Peregrine Pharmaceuticals is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for cancer therapy and diagnostics. The company has two platforms and is advancing multiple cancer clinical programs, including its lead immuno-oncology candidate bavituximab, its PS-targeting agent, 124I-PGN650 (PGN650), and its brain cancer treatment Cotara. Bavituximab is the company’s therapeutic PS-targeting antibody, while PGN650 is its PS-targeting imaging agent. The company has conducted three randomized Phase II clinical trials of bavituximab in combination with standard chemotherapy for front-line and second-line NSCLC as well as front-line pancreatic cancer. Additionally, it has four ongoing ISTs evaluating bavituximab in combination with other drugs for various other tumor indications.